Dexamethasone Palmitate for PONV After Minimally Invasive Endoscopic Surgery

Launched by BEIJING TIANTAN HOSPITAL · May 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called dexamethasone palmitate to see if it can help prevent nausea and vomiting that some patients experience after minimally invasive surgeries, like laparoscopic or thoracoscopic procedures. Even though dexamethasone is commonly used for this purpose, many patients still face nausea after surgery. Dexamethasone palmitate may work better and have fewer side effects, so researchers want to find out how effective and safe it is for patients.

To participate in this trial, you need to be between 18 and 65 years old and scheduled for an elective minimally invasive surgery with general anesthesia. However, you cannot be allergic to dexamethasone or have certain medical conditions, like severe heart or kidney issues. If you join the study, you will receive the medication before your surgery, and the team will monitor you afterward to see how well it works in preventing nausea. This trial is not yet recruiting participants, but it aims to help improve care for patients undergoing these types of surgeries in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18 to 65 years;
• • Providing written informed consent;
• • Perform elective minimally invasive endoscopic surgery (laparoscopic surgery, thoracoscopic surgery) undergoing general anesthesia.
• Exclusion Criteria:
• • Known to be allergic to dexamethasone;
• • Any systemic glucocorticoids within 3 months before trial entry;
• • History of severe heart disease, liver/kidney failure, or systemic rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, et al);
• • Cognitive impairment or severe mental illness;
• • Uncontrolled diabetes or infectious diseases;
• • Pregnancy or breastfeeding.